Orion Oyj (ORINY) Stock Price & Analysis
Orion Oyj (ORINY) — price $56.77 (-1.77%), as of the Nov 18, 2026 trading session; market cap $15.9B.
Educational signal · not a buy or sell recommendation · How to read this
Orion Oyj · ORINY · Healthcare · Drug Manufacturers - General
Orion Oyj is a Finnish pharmaceutical company specializing in the creation, production, and commercialization of medicines for both human and animal health, as well as the active components (APIs) essential for drug…
Price as of Nov 18, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $56.77 | |
| Change on the day | -1.77% | |
| 52-week range | $33.63–$58.15 | |
| Market capitalisation | $15.9B | — |
| Price / earnings (trailing) | 21.71 | |
| Shares traded on the day | 115 | |
| Beta (volatility vs the S&P 500) | 0.29 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Orion Oyj (ORINY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Orion Oyj (ORINY), and what does it report?
Short answer
Orion Oyj is a Finnish pharmaceutical company specializing in the creation, production, and commercialization of medicines for both human and animal health, as well as the active components (APIs) essential for drug… Healthcare / Drug Manufacturers General Headquarters: Orionintie 1A, Espoo, UU, 02200, FI. It employs 4,029 people and is led by Aino Anna Liisa Hurme. In Q3 FY2026 it reported revenue of €542M and net income of €168M. The market values it at $15.9B.
What do the latest results show for Orion Oyj (ORINY)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of €542M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | €542M | €168M | €0.30 (diluted) |
| Q2 FY2026 | €522M | €140M | €0.25 (diluted) |
| Q1 FY2026 | €418M | €90M | €0.16 (diluted) |
| Q4 FY2025 | €695M | €261M | €0.46 (diluted) |
What are the financial strengths and risks for Orion Oyj (ORINY)?
Short answer · as of
The distress and quality screens read Altman Z 31.65 · Piotroski F 7. Trailing ratios: ROE 54.5% · ROA 27.4% · current ratio 2.72.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ORINY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ORINY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Orion Oyj (ORINY)?
- Orion Oyj (HLSE:ORNBV) Stock Richly Valued Despite Q3 Earnings Surge
- Orion Group Interim report January–September 2026: Strong financial performance and positive developments in the R&D pipeline
- Is Orion Oyj (HLSE:ORNBV) Fully Priced On Phase 3 Darolutamide Trial News?
- Changes in Orion Group’s Executive Team as of 1 January 2027
Orion Oyj Healthcare Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the ORINY research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is ORINY a good stock to buy?
Stock Expert AI does not rate ORINY buy, sell or hold. Orion Oyj has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ORINY stock price today?
The last price recorded for Orion Oyj (ORINY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does Orion Oyj ensure product innovation and development?
Orion Oyj ensures product innovation and development through a combination of in-house research and strategic external collaborations. The company invests in its own R&D capabilities to advance its human and veterinary pharmaceutical pipelines.
What are the key factors to evaluate for ORINY?
Evaluate ORINY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Expansion of Oncology Portfolio: Orion Oyj's Nubeqa, for prostate cancer, represents a significant growth driver. Not financial advice.
How frequently does ORINY data refresh on this page?
ORINY's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ORINY's recent stock price performance?
Orion Oyj (ORINY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio spanning human prescription, self-care, and veterinary pharmaceuticals, reducing revenue concentration risk. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ORINY overvalued or undervalued right now?
The trailing P/E of Orion Oyj (ORINY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ORINY before investing?
Before investing in Orion Oyj (ORINY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 16 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com